Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab delayed-start study in episodic cluster headache
NL-OMON52070Phase 3Active, not recruiting
- Sponsor
- Lundbeck
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eptinezumab in Cluster Headache (CH) (2 arms), sponsored by Lundbeck. Primary endpoint: Change from baseline in number of weekly attacks. Started Dec 2021; status: active, not recruiting.
02
Drugs
eptinezumab
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on NL-OMON52070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52070.